FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

GHRP-2

Pralmorelin / Growth Hormone Releasing Peptide-2 / KP-102

Growth Hormone Secretagogues

GHRP-2 (Growth Hormone Releasing Peptide-2, also known as Pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin/GHS-R1a receptor with higher potency and selectivity than its predecessor GHRP-6. It produces robust growth hormone pulses comparable to GHRP-6 but with significantly less appetite stimulation and ghrelin-like hunger effects, making it preferred for applications where appetite increase is undesirable. Research applications include GH deficiency diagnostics, anti-aging protocols, muscle wasting, and body composition optimization.

작용 메커니즘

Synthetic hexapeptide GHSR agonist. Stimulates GH release via ghrelin receptor activation on pituitary somatotrophs. Also increases appetite (ghrelin mimetic), cortisol, and prolactin at higher doses. Produces stronger GH pulses than ipamorelin but less selective.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 100-300mcg 2-3 times daily via subcutaneous injection on an empty stomach. Often combined with a GHRH analog. Higher doses (>300mcg) increase cortisol and prolactin without proportional GH increase.

연구 노트

Clinical Research Status

GHRP-2 (Pralmorelin) has been approved in Japan as a diagnostic agent for growth hormone deficiency under the trade name GHRP Kaken, making it one of the few GHRPs with any regulatory approval globally. It has been studied in numerous clinical trials for applications including GH deficiency assessment, short stature in children, and catabolic states. The compound continues to be widely used in research and clinical settings, with ongoing interest in its potential therapeutic applications for sarcopenia and age-related GH decline.

Key Published Findings

Clinical studies demonstrate that GHRP-2 produces GH release of similar magnitude to GHRP-6 (10-20 fold above baseline) but with approximately 50% less ghrelin receptor-mediated appetite stimulation. Research in elderly subjects confirms maintained GHRP-2 responsiveness even when natural GHRH sensitivity has declined with age, and synergistic effects with GHRH co-administration can produce GH peaks exceeding 50 ng/mL. Studies have shown that GHRP-2 increases IGF-1 levels, improves nitrogen balance, and promotes lean body mass accretion during repeated administration protocols of 4-12 weeks duration.

Safety Profile

GHRP-2 demonstrates excellent tolerability in clinical studies with side effects generally limited to transient facial flushing and mild water retention. Cortisol and prolactin elevations are modest and clinically insignificant at standard research doses. The reduced appetite stimulation compared to GHRP-6 makes it better tolerated by users managing caloric intake, and no serious adverse events have been attributed to the compound in published research.

Drug Interactions & Contraindications

As with other GH secretagogues, GHRP-2 may transiently affect insulin sensitivity during acute GH release phases, warranting glucose monitoring in diabetic patients. Synergistic interaction with GHRH analogs is well-documented and intentionally exploited in clinical protocols but requires appropriate dose adjustment. Glucocorticoid use may blunt GHRP-2 response, and somatostatin analogs (octreotide) will directly antagonize its GH-releasing effects.

Comparison to Related Compounds

GHRP-2 is considered the best balance of GH-releasing potency and side effect profile among the GHRP family, producing strong GH output without the extreme hunger of GHRP-6 or the desensitization issues of Hexarelin. Ipamorelin is more selective with even fewer side effects but produces approximately 30-40% less GH release per dose compared to GHRP-2. MK-677 (Ibutamoren) offers oral convenience with 24-hour GH elevation but produces more sustained appetite increase and water retention than pulsatile GHRP-2 injections.

Community Observations

Users typically administer GHRP-2 at 100-300mcg subcutaneously 2-3 times daily, commonly paired with Mod GRF 1-29 for synergistic GH release, with most reporting it as the gold standard balance of efficacy and tolerability. Mild appetite increase is reported by some users but is notably less disruptive than GHRP-6, making GHRP-2 compatible with caloric restriction phases. The community consensus positions GHRP-2 as the preferred injectable GH secretagogue for long-term use due to sustained efficacy without the tolerance development seen with Hexarelin.

반감기

~1-2 hours

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 18 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

PralmorelinGrowth Hormone Releasing Peptide-2KP-102

자주 묻는 질문

GHRP-2란 무엇인가요?

GHRP-2 (Growth Hormone Releasing Peptide-2, also known as Pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin/GHS-R1a receptor with higher potency and selectivity than its predecessor GHRP-6. It produces robust growth hormone pulses comparable to GHRP-6 but with significantly less appetite stimulation and ghrelin-like hunger effects, making it preferred for applications where appetite increase is undesirable. Research applications include GH deficiency diagnostics, anti-aging protocols, muscle wasting, and body composition optimization.

GHRP-2는 어떻게 작용하나요?

Synthetic hexapeptide GHSR agonist. Stimulates GH release via ghrelin receptor activation on pituitary somatotrophs. Also increases appetite (ghrelin mimetic), cortisol, and prolactin at higher doses. Produces stronger GH pulses than ipamorelin but less selective.

GHRP-2의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

GHRP-2의 반감기는 얼마인가요?

~1-2 hours

GHRP-2의 다른 이름은 무엇인가요?

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기